158 related articles for article (PubMed ID: 31168457)
21. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
[TBL] [Abstract][Full Text] [Related]
22.
Zhang Z; Chen S; Chen S; Chen G; Zhang R; Li J; Qu J
Oncotarget; 2017 Sep; 8(41):69916-69923. PubMed ID: 29050251
[TBL] [Abstract][Full Text] [Related]
23. Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia.
Kashyap MK; Karathia H; Kumar D; Vera Alvarez R; Forero-Forero JV; Moreno E; Lujan JV; Amaya-Chanaga CI; Vidal NM; Yu Z; Ghia EM; Lengerke-Diaz PA; Achinko D; Choi MY; Rassenti LZ; Mariño-Ramírez L; Mount SM; Hannenhalli S; Kipps TJ; Castro JE
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102202. PubMed ID: 38846999
[TBL] [Abstract][Full Text] [Related]
24. Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.
Vetro C; Haferlach T; Jeromin S; Stengel A; Zenger M; Nadarajah N; Baer C; Weissmann S; Kern W; Meggendorfer M; Haferlach C
Br J Haematol; 2018 Oct; 183(1):47-59. PubMed ID: 30022491
[TBL] [Abstract][Full Text] [Related]
25. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract][Full Text] [Related]
26. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
Rani L; Gogia A; Singh V; Kumar L; Sharma A; Kaur G; Gupta R
Ann Hematol; 2019 Feb; 98(2):437-443. PubMed ID: 30338367
[TBL] [Abstract][Full Text] [Related]
27. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
28. The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.
Chen L; Li J; Zheng W; Zhang Y; Wu Y; Li L; Qian S; Xu W
Leuk Lymphoma; 2007 Sep; 48(9):1785-92. PubMed ID: 17786715
[TBL] [Abstract][Full Text] [Related]
29. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
[TBL] [Abstract][Full Text] [Related]
30. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
31. Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia.
Zhu DX; Fan L; Lu RN; Fang C; Shen WY; Zou ZJ; Wang YH; Zhu HY; Miao KR; Liu P; Xu W; Li JY
Cancer Sci; 2012 May; 103(5):875-81. PubMed ID: 22320315
[TBL] [Abstract][Full Text] [Related]
32. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
33. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
34. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
35. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
[TBL] [Abstract][Full Text] [Related]
36. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
[TBL] [Abstract][Full Text] [Related]
37. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
[TBL] [Abstract][Full Text] [Related]
38. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
Quesada V; Conde L; Villamor N; Ordóñez GR; Jares P; Bassaganyas L; Ramsay AJ; Beà S; Pinyol M; Martínez-Trillos A; López-Guerra M; Colomer D; Navarro A; Baumann T; Aymerich M; Rozman M; Delgado J; Giné E; Hernández JM; González-Díaz M; Puente DA; Velasco G; Freije JM; Tubío JM; Royo R; Gelpí JL; Orozco M; Pisano DG; Zamora J; Vázquez M; Valencia A; Himmelbauer H; Bayés M; Heath S; Gut M; Gut I; Estivill X; López-Guillermo A; Puente XS; Campo E; López-Otín C
Nat Genet; 2011 Dec; 44(1):47-52. PubMed ID: 22158541
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
40. Low prevalence and independent prognostic role of del(11q) in Chinese patients with chronic lymphocytic leukemia.
Zou YX; Tang HN; Zhang J; Tang XL; Qin SC; Xia Y; Zhu HY; Qiao C; Wang L; Fan L; Xu W; Li JY; Miao Y
Transl Oncol; 2021 Oct; 14(10):101176. PubMed ID: 34273750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
